In MECP2 duplication syndrome OMIM 300260 (MECP2, OMIM 300260), the master switch sits on the ↑ UP branch ([F] forced below); the healthy state is the OFF well. The forced corrective direction is to lower s toward OFF branch (polarity: clear). Classification: ○ Novel direction-only lead. Direction only — no dose, no efficacy magnitude.
The disease maps to an R19 double-well whose corrective lever is read straight off the cusp (barrier 0.5588, γ 1.4951, spinodal 0.7036). The corrective direction is forced [F]; the agent names below are direction-concordant labels at grade [O] (no dose, no efficacy or safety magnitude). This is a research hypothesis offered to experts, not medical advice.
The emergence switch
The switch for MECP2 duplication syndrome OMIM 300260 is an R19 double-well emerged from the real proximal-promoter DNA of MECP2. Its geometry is fixed by measured stiffness γ (never fitted); the numbers below are read directly off that cusp.
emergent axis
↑ UP [F]
healthy branch
OFF
lesion
GOF
γ (stiffness)
1.4951
barrier
0.5588
spinodal
0.7036
s_on / s_off
1.2227 / -1.2227
fragility
0.18
corrective polarity
clear
forced direction
lower s toward OFF branch
Chemistry feasibility (DIRECTION only [O]). small-molecule recrossing of the fold is geometrically harder (barrier 0.5588 at neutral drive; lower barrier = smaller drive to supply). [O] -- no affinity/potency/dose/efficacy asserted.
The derived corrective lever
The cusp forces a corrective direction: lower s toward OFF branch. This is the load-bearing output of the framework — it is [F] forced, and it is falsifiable. 2 lever families are derived; the lead is h-restore (drive modulator).
Mechanism. remove / oppose the drive (clear the accumulating load that pins the disease branch)
Applies to. allele-agnostic (downstream/environmental tilt)
favoured when the switch is fragile -- a small drive shift recrosses the fold
Falsifier. If clearing/opposing the accumulating MECP2 does NOT relieve the disease branch in a MECP2 model, the h-restore(clear) lever is refuted for this axis.
EXCLUDED: gain-of-function -- the lesion is not a destabilised healthy product to stiffen; the corrective move is to clear/oppose the toxic drive (h-restore)
Falsifier. If a folding-stabiliser/chaperone does NOT re-deepen the healthy well for a residual MECP2 allele (no rescue that a null allele lacks), the gamma-restore lever is refuted; null alleles are excluded by construction.
Agents mapped onto the lever
Existing agents whose known action is direction-concordant with the derived lever (status as pinned in the corpus; no dose, no efficacy magnitude).
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.
Direction-only candidate leads (corpus join)
Each lead is surfaced only because its known mechanism points the same way as the derived lever, and each comes with a source and a falsifier. None is a treatment.
Mechanism. An investigational antisense oligonucleotide that lowers the MECP2 transcript and MeCP2 protein, opposing the excess MeCP2 dosage that drives MECP2 duplication syndrome. Direction on the disease axis: decrease -- clear the over-abundant product of the duplicated gene. Engaged node: MECP2 (shared with Rett syndrome, which is a LOF node deriving the OPPOSITE direction; the sign filter isolates this agent to the duplication node only). Allele scope: agnostic. Because MeCP2 is dosage-sensitive, the corrective window is bounded -- over-lowering toward the Rett range is a theoretical concern, a direction statement rather than a magnitude. Addresses the honest-miss reason (no approved MeCP2-lowering agent). INVESTIGATIONAL direction-only hypothesis (no efficacy/approval/availability claim); status per training knowledge plus a 2026-06 web check (ATTUNE first-in-human) -- confirm current development.
Prior-art. Direction-only hypothesis: the geometry derives a decrease (clear the over-abundant product) for the MECP2 GOF/duplication node; the investigational MECP2-lowering antisense oligonucleotide ION440 reduces MeCP2, a matched decrease, addressing the honest-miss reason (no approved MeCP2-lowering agent). First-in-human (ATTUNE, Baylor, 2024). The sign filter isolates this from the MECP2 LOF Rett node, which derives the opposite direction. Investigational; confirm current status. No efficacy/availability claim.
Safety (qualitative; no magnitude). investigational CNS-delivered antisense oligonucleotide; delivery and dose-finding considerations (qualitative; no magnitude); MeCP2 is dosage-sensitive, so over-lowering toward the Rett range is a theoretical bound (a direction statement, not a magnitude); confirm current development status
Falsifier. If ION440 (a gene-specific decrease agent) clearing/opposing the accumulating load does NOT relieve the UP [F] disease branch in a MECP2 model, the h-restore(clear) direction is refuted for ION440 here.
Source: ION440 (Ionis) MECP2-lowering antisense oligonucleotide; first-in-human ATTUNE study in MECP2 duplication syndrome
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.
Evidence & provenance
What is reproduced vs. cited for this page.
element
grade
basis
R19 switch & cusp geometry (this page)
[V] verified
emerged from measured promoter γ of MECP2; deterministic, 2×sha256 identical
corrective direction
[F] forced
forced by the cusp sign; falsifiable (see lever falsifiers)
mapped agents / leads
[O] open
direction-concordance only; corpus-pinned (2026-06-21); no dose, no efficacy/safety magnitude
Reading the agent column. VALIDATION SIGNAL -- the agent is already approved / established standard for this disease, so the direction logic recovered known clinical practice. Not a new claim by this kit. GENUINE HYPOTHESIS -- no approved indication for this disease; the direction match is a direction-only, untested [O] lead. Basis field grades the evidence (investigational here / in a related condition / off-label / speculative).